Advanced in Philadelphia-Negative Chronic Myeloid Leukemia

Dr. Eunice S. Wang

Hematology Oncology | Hematology | Oncology
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eunice Wang is a Hematologist Oncology specialist and a Hematologist in Buffalo, New York. Dr. Wang is rated as an Advanced provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 233 peer reviewed articles and participating in 30 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

ROSWELL PARK CANCER INSTITUTE
Elm And Carlton St, Buffalo, NY 14263

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials

Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Ivosidenib, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Suspended
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, IMGN632, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 17, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Azacitidine
Study Phase: Phase 1
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: Tagraxofusp
Study Phase: Phase 1/Phase 2
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drug: IMGN-632 CD123-Targeting Antibody-Drug Conjugate
Study Phase: Phase 1/Phase 2
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Other, Drug
Study Drugs: Gemtuzumab, Talazoparib, Talazoparib Tosylate
Study Phase: Phase 1
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Enrollment Status: Terminated
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: ONO-7475, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: February 21, 2024
Intervention Type: Drug
Study Drug: SKI-G-801
Study Phase: Phase 1
A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations
A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Phase: Phase 2
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multi-Center, Open-Label Phase 1b/2 Study of Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Adult Patients With Relapsed/Refractory B Lineage Acute Lymphoblastic Leukemia (B-ALL)
A Multi-Center, Open-Label Phase 1b/2 Study of Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Adult Patients With Relapsed/Refractory B Lineage Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Withdrawn
Publish Date: January 28, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Inotuzumab, Vincristine
Study Phase: Phase 1/Phase 2
A Phase I/II Study of CPI-613 and Hydroxychloroquine for Patients With High Risk MDS Who Have Failed Hypomethylating Therapy
A Phase I/II Study of CPI-613 and Hydroxychloroquine for Patients With High Risk MDS Who Have Failed Hypomethylating Therapy
Enrollment Status: Withdrawn
Publish Date: April 14, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study
Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study
Enrollment Status: Completed
Publish Date: November 15, 2019
A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 04, 2019
Intervention Type: Drug
Study Phase: Phase 1
Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML
Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML
Enrollment Status: Completed
Publish Date: February 28, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia
Enrollment Status: Completed
Publish Date: February 09, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 29 Less Clinical Trials

233 Total Publications

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 25, 2025
Similar Doctors
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. James E. Thompson
Hematology Oncology | Hematology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. James E. Thompson
Hematology Oncology | Hematology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Thompson is a Hematologist Oncology specialist and a Hematologist in Buffalo, New York. Dr. Thompson is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Childhood Acute Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Elizabeth A. Griffiths
Hematology Oncology | Hematology | Oncology
Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Elizabeth A. Griffiths
Hematology Oncology | Hematology | Oncology
Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Elizabeth Griffiths is a Hematologist Oncology specialist and a Hematologist in Buffalo, New York. Dr. Griffiths is rated as an Elite provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration.

Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Peter G. Maslak
Hematology
Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Peter G. Maslak
Hematology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Peter Maslak is a Hematologist in Buffalo, New York. Dr. Maslak is rated as an Advanced provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Gastric Lymphoma, Non-Hodgkin Lymphoma, Acute Promyelocytic Leukemia, Leukemia, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wang's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 14 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile